Recent News

• 06.05.2025 - Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio
• 06.05.2025 - Thérapeutique Knight et Sumitomo Pharma signent des ententes exclusives de licence de commercialisation du portefeuille canadien de Sumitomo
• 05.13.2025 - Knight présentera à la conférence sur la santé internationale de 2025 de RBC Marchés des Capitaux à New York
• 05.13.2025 - Knight to Present at the 2025 RBC Capital Markets Global Healthcare Conference in New York City
• 05.08.2025 - Knight Therapeutics Reports First Quarter 2025 Results

Recent Filings

• 05.28.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.28.2025 - D Notice of Exempt Offering of Securities
• 05.28.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.27.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.22.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.22.2025 - 8-K Current report
• 05.22.2025 - EX-99.1 EX-99.1
• 05.21.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 4 Statement of changes in beneficial ownership of securities